SMTI (Sanara MedTech, Inc.) Market Value to Book Value Ratio

Official company branding of sanaramedtech.com (SMTI)

Sanara MedTech Inc. (SMTI) management is betting on cutting-edge developments in dermatology and tissue regeneration by expanding direct supplies to clinics. Production processes have been fully outsourced to third-party contractors, allowing the company to focus on R&D. Due to the unique properties of its products, Sanara MedTech Inc. (SMTI) competes effectively in the surgery segment, maintaining a margin of 37.83. This chart illustrates the share price dynamics below.

SMTI sanaramedtech.com: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Sanara MedTech Inc. (SMTI)

- price and consensus price forecast:
Stock Price sanaramedtech.com|SMTI - Analyst Median Target
- market capitalization data:
Market Value Sanara|SMTI - Full Business Value
- book capitalization data:
Book Value per Share Sanara MedTech|SMTI - Accounting Value of Company|Market Capitalization to Book Value Ratio sanaramedtech.com|SMTI - Company Total Assets
- debt and liquidity data:
Debt to Equity Sanara MedTech Inc.|SMTI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity sanaramedtech.com|SMTI - Company Total Debt|Debts to Book Capitalization Sanara|SMTI - Company Long-Term Debts|Company Current Liabilities Sanara MedTech
Initial company analysis:Sanara MedTech, Inc. - SMTI
Original product of sanaramedtech.com

The integration of ESG principles and rigorous quality control in the production of surgical instruments at Sanara MedTech Inc. (SMTI) creates intangible value, which is reflected in the ratio of market capitalization to book value. This multiple measures the business's market price relative to its accounting assets, allowing investors to assess the premium paid for future growth or the risk of a price correction should monetary conditions shift.

Main competitors

Krystal Biotech, Inc. - Market Capitalization to Book Value Ratio|APGE (apogeetherapeutics.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Arcutis Biotherapeutics, Inc. ARQT|Market Capitalization to Net Assets Vericel Corp|Oruka Corp (ORKA) - Market Capitalization to Book Value Ratio|Market Value to Book Value dbv-technologies.com (DBVT)|Market Capitalization to Book Value Ratio SLSN (Solesence)|Journey Medical Corp - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Forte Biosciences (FBRX)|EMPG: Market Value to Book Value|SLGL (Sol-Gel) - Market Value to Book Value Ratio|AXIL Brands (AXIL) - Market Cap to Net Assets Ratio|MDCX (Medicus Pharma Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Verrica (VRCA)|Hoth Therapeutics, Inc. (HOTH) - Market Cap to Net Assets Ratio|Market Value to Book Value BFRI (biofrontera-us.com)|Market Value to Book Value Ratio VYNE|Sonoma Pharmaceuticals Inc. - Market Capitalization to Book Value|Quoin Pharma - Market Value to Book Value Ratio|AZTR - Market Capitalization to Book Value Ratio|Dermata Therapeutics, Inc. - Market Capitalization to Book Value Ratio|ELAB (Elevai Labs Inc) - Market Capitalization to Book Value|Market Value to Book Value Ratio Revance Therapeutics, Inc (RVNC)